These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32296919)

  • 1. PD-1
    Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A
    Cancer Immunol Immunother; 2020 Aug; 69(8):1505-1517. PubMed ID: 32296919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
    He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
    Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
    Fujita K; Yamamoto Y; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
    Thorac Cancer; 2020 Jan; 11(1):15-18. PubMed ID: 31701630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Sánchez-Magraner L; Miles J; Baker CL; Applebee CJ; Lee DJ; Elsheikh S; Lashin S; Withers K; Watts AG; Parry R; Edmead C; Lopez JI; Mehta R; Italiano A; Ward SG; Parker PJ; Larijani B
    Cancer Res; 2020 Oct; 80(19):4244-4257. PubMed ID: 32855204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab for the treatment of non-small cell lung cancer.
    Santini FC; Rudin CM
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
    Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H
    Clin Cancer Res; 2019 May; 25(10):3026-3034. PubMed ID: 30765392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.